Canoe Financial LP trimmed its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 27.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,741 shares of the medical instruments supplier's stock after selling 11,100 shares during the quarter. Canoe Financial LP's holdings in Becton, Dickinson and Company were worth $6,583,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in shares of Becton, Dickinson and Company by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 26,743,052 shares of the medical instruments supplier's stock valued at $6,067,196,000 after purchasing an additional 184,288 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of Becton, Dickinson and Company by 36.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 12,126,707 shares of the medical instruments supplier's stock valued at $2,751,187,000 after purchasing an additional 3,219,317 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Becton, Dickinson and Company by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 6,351,537 shares of the medical instruments supplier's stock valued at $1,437,161,000 after purchasing an additional 66,024 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Becton, Dickinson and Company by 15.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 6,175,899 shares of the medical instruments supplier's stock worth $1,401,126,000 after acquiring an additional 810,345 shares in the last quarter. Finally, First Eagle Investment Management LLC increased its holdings in Becton, Dickinson and Company by 31.4% in the 4th quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock worth $1,004,132,000 after acquiring an additional 1,057,879 shares in the last quarter. 86.97% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages recently commented on BDX. Morgan Stanley cut their price target on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an "overweight" rating for the company in a report on Tuesday, May 6th. Citigroup lowered shares of Becton, Dickinson and Company from a "strong-buy" rating to a "hold" rating and cut their price target for the stock from $217.00 to $185.00 in a report on Thursday, May 22nd. Barclays cut their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a report on Tuesday, June 3rd. The Goldman Sachs Group lowered shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 price target for the company. in a report on Friday, May 2nd. Finally, Piper Sandler lowered shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and cut their price target for the stock from $260.00 to $185.00 in a report on Friday, May 2nd. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus target price of $219.22.
View Our Latest Report on Becton, Dickinson and Company
Insider Activity
In related news, EVP Michael David Garrison sold 479 shares of the business's stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total value of $94,497.12. Following the sale, the executive vice president now directly owns 4,887 shares in the company, valued at approximately $964,107.36. The trade was a 8.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David Shan sold 1,166 shares of the business's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the completion of the sale, the executive vice president now owns 4,575 shares in the company, valued at approximately $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.36% of the company's stock.
Becton, Dickinson and Company Trading Down 0.0%
Shares of BDX opened at $168.58 on Friday. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70. The firm's fifty day moving average is $179.58 and its two-hundred day moving average is $211.27. The stock has a market cap of $48.32 billion, a PE ratio of 32.17, a price-to-earnings-growth ratio of 1.27 and a beta of 0.25.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating the consensus estimate of $3.28 by $0.07. The firm had revenue of $5.27 billion for the quarter, compared to analysts' expectations of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The company's revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.17 EPS. Research analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.
Becton, Dickinson and Company Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be given a dividend of $1.04 per share. The ex-dividend date is Monday, June 9th. This represents a $4.16 annualized dividend and a dividend yield of 2.47%. Becton, Dickinson and Company's payout ratio is 79.39%.
Becton, Dickinson and Company Company Profile
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
